ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lundbeck buys firm for Parkinson’s drug

by Lisa M. Jarvis
March 26, 2018 | APPEARED IN VOLUME 96, ISSUE 13

 

09613-buscon17-foliglurax.jpg

Lundbeck is acquiring Prexton Therapeutics, which was spun off of Merck KGaA in 2012, for up to $1.1 billion. The centerpiece of the deal is foliglurax, a positive allosteric modulator of mGluR4 currently in Phase II studies in people with Parkinson’s disease. Foliglurax was developed by Merck and Domain Therapeutics, which in 2013 sold rights to the drug to Prexton. The compound addresses side effects of current Parkinson’s treatments, which alleviate symptoms by replacing dopamine but can cause involuntary muscle movements.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment